Physician profile
Regan C Pyle
NPI 1992977896
$71,778.08
in general payments reported to CMS, 2019-2025
19 companies · $33K in 2025
The $33K reported for 2025 was more than what 94% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $46.90 · 2021: $290 · 2022: $8,033 · 2023: $10K · 2024: $19K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $7,457 · Food and Beverage: $3,546 · Honoraria: $1,246 · Education: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,801.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,490.00 |
| Travel and Lodging | $7,457.39 |
| Food and Beverage | $3,546.04 |
| Honoraria | $1,245.75 |
| Education | $608.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $33,733.39 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Genentech USA, INC. | $10,957.36 | 2022-2025 | Xolair |
| Incyte Corporation | $10,530.99 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $8,286.60 | 2023-2025 | |
| Genzyme Corporation | $4,164.49 | 2019-2025 | |
| Blueprint Medicines Corporation | $2,977.11 | 2024-2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $588.14 | 2019-2025 | Dupixent |
| Amgen INC. | $101.81 | 2020-2025 | Tezspire |
| Lilly USA, LLC | $98.50 | 2021-2025 | Ebglyss |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Glaxosmithkline, LLC. | $55.11 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.37 | 2023-2024 | Hyqvia, Cuvitru |
| Regeneron Pharmaceuticals, INC. | $30.23 | 2023 | Dupixent |
| Horizon Therapeutics Plc | $23.01 | 2021 | |
| Optinose US, INC. | $20.47 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $20.11 | 2024 | Ruconest |
| Kaleo, INC. | $16.79 | 2020 | |
| Galderma Laboratories, L.P. | $16.34 | 2025 | Nemluvio |
| Pfizer INC. | $15.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regan Pyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.